Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Kiora Commences Mid-Stage Rare Eye Disease Study

Kiora Pharmaceuticals (NASDAQ:KPRX) enrols the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED).

The Phase 2 clinical trial is designed as a single-arm, open label ten patient (up to 20 eyes) study, evaluating subjects 28 days after receiving KIO-201 six times daily.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.